Noticeboard

The Radala Foundation is looking for established, leading principal investigators eligible for 200,000 CHF (~£181,500 GBP) research funding to pursue a potentially ground-breaking, high-risk project for 2 years in basic research in ALS. 

Principal Investigators (PI) are expected to be active researchers who have a track-record of significant research achievements in the last 10 years. Investigators active in ALS research or in broadly related fields are encouraged to submit proposals relevant to ALS. Research must be conducted in a public or private research organisation (known as a host institution).

The goal of the Radala foundation is to provide research grants for the study of the understanding of the basic causes of the disease. These awards are not directed to clinically related projects for patient care. There is no geographical limitation to the recipients of these grants. 

Application deadline: 30 June 2025

Find out more and apply

The Frick Foundation is looking for talented early-career scientists who have already produced excellent supervised work, ready to work independently and shows potential to be a research leader. Post-doctoral fellows are not eligible. Two researchers will receive 100,000 Swiss francs (~£90,700 GBP) each that can be used over 2 years.

Researchers of any nationality with 5 years of experience since completion of their PhD, a scientific track record showing great promise and an excellent research proposal can apply.

Research must be conducted in a public or private research organisation (known as a host Institution).

Application Deadline: 30 June 2025

Find out more and apply

The Corsalex Postdoctoral Fellowship Program is designed to support promising early-career researchers who wish to enter or continue research in the field of C9orf72 MND/FTD. 

Fellows receive up to $210,000 over 3 years to support research of high scientific merit and relevance to C9 MND.

Applications are open to Junior postdoctoral researchers with a designated advisor in an ALS or FTD-focused lab. Researchers must be no more than 1 year into postdoctoral fellowship.

Corsalex are interested in projects that focus on:

• The underlying biology of C9orf72 MND/FTD
• Novel drug targets or biomarkers
• Gene therapies
• Drug delivery into the CNS
• Disease models

Application Deadline: 1 July

Find out more and apply

The Sean M. Healey International Prize for Innovation in ALS is now accepting nominations.

This is a global prize celebrating excellence in research for a team of investigators who catalyse exceptional discoveries leading to a transformative advance in therapy development in ALS. 

The award will be presented at the International Symposium on ALS/MND in San Diego, USA on the 5-7 December 2025. The selected nominee will be awarded $50,000 USD and travel reimbursement up to $2,500 USD to attend International Symposium on ALS/MND.

Prize Criteria

Team of investigators who made a significant advance in the ALS field impacting the development of novel therapies for ALS, including, but not limited to the following:

• A technology to identify novel targets for drug development
• A technology to advance therapy development for ALS
• Tools or targets to stratify the ALS population and improve clinical trial design
• A global, multiple disciplinary collaboration that leads to new insights into the biology of the disease and translates into novel approaches for therapy development
• A novel outcome measure to improve efficiency in clinical trials in patients with ALS

Nomination Deadline: 9 July

Find out more and apply 

The Rob Burrow Early Career Researcher Prize is a new initiative created by the MND Association in memory of our late patron Rob Burrow CBE. It is being established as an annual competition to acknowledge the contribution of an outstanding UK-based Early Career Researcher in advancing scientific understanding or treatment in the field of ALS/MND. 

The Prize comprises a commemorative medal, a research stipend of £10,000 and a £2,000 bursary to attend the MND Association’s International Symposium on ALS/MND.

The Prize will be announced at the UK MND Research Institute Symposium, held at University College London on 5 September, at which the winner will give a brief presentation on their research.

Application deadline: 28 July

Find out more and apply

The Lalji Family ALS Award is accepting nominations for individual or team of investigators who have made significant progress impacting the repair and regeneration of neuronal degeneration that may be applied in ALS.

This is a global award celebrating excellence in research for an individual or team of investigators who are making transformative breakthroughs in the science of repair and regeneration of neurological function.

The award will be presented at the International Symposium on ALS/MND in San Diego, USA on the 5-7 December 2025. The selected nominee will be awarded $40,000 USD.

Prize Criteria

• Applicant must have an MD, PhD or equivalent degree and be a leader in the field of ALS or regenerative medicine/biology with a strong publication record.
• The proposal must have a strong scientific rationale with a focus on repair of neurological function.
• Inclusion of preliminary findings demonstrating approach and feasibility in pre-clinical models is recommended.
• International applicants are encouraged to apply.

Nomination deadline: 3 September

Find out more and apply

The Longitude Prize on ALS is a £7.5m prize, of which the MND Association is the principal funder, that aims to identify, prioritise and validate high-potential drug targets for ALS. The international programme seeks to incentivise the use of AI-based approaches to transform therapeutic discovery for the treatment of ALS, the most common form of MND.

The five-year Prize will see global multidisciplinary teams collaborate and compete in a three-phased programme. These phases are: 

1. Discover- this stage will see 20 teams use AI-based methods to analyse datasets over 9 months to identify novel therapeutic targets for ALS, or provide new evidence for known but unvalidated targets. The award for this stage is £100,000.
2. Prioritise- Ten of the teams from the first stage will then spend 12 months using computational and lab analysis to strengthen confidence in, and expand the evidence base for, the proposed therapeutic targets. Teams may continue to develop up to 10 targets submitted from Stage 1 and will further narrow this list based on emerging evidence. The award for this stage is £200,000.
3. Validate- Five of the teams from stage 2 will carry out comprehensive wet lab validation of the most promising therapeutic target(s) for 24 months. This stage is predominantly lab-based and aims to generate high-confidence data that can move targets closer to clinical application. The award for this stage is £500,000.

The Prize will award one winner who has demonstrated exceptional progress in validating therapeutic target(s) with the highest potential impact on ALS treatment. The winner will receive a £1 million award. 

Challenge Works are are looking for the brightest minds to bring AI to the fight against ALS.

The Prize will award applicants from across medical research, biotechnology, computational biology and AI with bold ideas on how to harness the power of AI to identify and validate high-potential therapeutic targets for the discovery of transformative ALS therapeutics.

They are looking for:

• AI experts

• Computational biologists and bioinformaticians

• Neurodegenerative disease researchers and ALS researchers

• Biotechnology, techbio and pharmaceutical companies

• Data scientists and engineers

• Clinical experts and medical researchers.

Deadline to register a team: 3 December 2025

Find out more and register as a team

The Sixth UCL Queen Square Motor Neuron Disease Centre International Symposium will be held in person at Queen Square in London and online. 

The programme includes talks on a range of topics from clincial trial updates to the development of new gene therapies and new targets for therapies in the future.

Registration is free.

Friday 5th September 2025 from 09:30am to 5:30pm (GMT).

Find out more and register.

World Congress of Neurology are committed to delivering a high-level scientific program, an international stage for your research, and plenty of networking opportunities. The XXVII World Congress of Neurology (WCN 2025) will take place on 12-15 October 2025 and will be held in Seoul, Korea.

Find out more and register

The key to defeating MND lies in fostering strong collaboration between leading researchers around the world, and sharing new understanding of the disease as rapidly as possible. This was the MND Association’s rationale behind the creation of the International Symposium on ALS/MND.

Each year, the Symposium attracts over 1,000 delegates, representing the energy and dynamism of the global MND research community. It is the largest medical and scientific conference specific to MND/ALS and is the premier event in the MND research calendar for discussion on the latest advances in research and clinical management. 

The 36th Symposium will be held in San Diego, USA in December.

Abstract submission and registration opens: Tuesday 6th May

Find out more